Surgical management of pancreatic neuroendocrine liver metastases
Pancreatic neuroendocrine tumors (PNET) are a heterogeneous group of neoplasms that vary in their clinical presentation, behavior and prognosis. The most common site of metastasis is the liver. Surgical resection of neuroendocrine liver metastases (NELM) is thought to afford the best long-term outco...
Saved in:
Published in | Journal of gastrointestinal oncology Vol. 11; no. 3; pp. 590 - 600 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
AME Publishing Company
01.06.2020
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Pancreatic neuroendocrine tumors (PNET) are a heterogeneous group of neoplasms that vary in their clinical presentation, behavior and prognosis. The most common site of metastasis is the liver. Surgical resection of neuroendocrine liver metastases (NELM) is thought to afford the best long-term outcomes when feasible. Initial preoperative workup should include surveillance for carcinoid syndrome, screening for evidence of liver insufficiency, and performance of imaging specific to neuroendocrine tumors such as a somatostatin receptor positron emission tomography scan. Standard surgical principles apply to hepatic surgery for NELM, namely prioritizing low central venous pressure anesthesia, minimizing blood loss, knowledge of liver anatomy, generous use of intraoperative ultrasound, as well as safe parenchymal transection techniques and practices to avoid bile leakage. Knowledge of established prognostic factors may assist with patient selection, which is important for optimizing short- and long-term outcomes of hepatic resection. Adjunct therapies such as concomitant liver ablation are used frequently and are generally safe when used appropriately. For patients with synchronous resectable NELM, resection of the primary either in a staged or combined fashion is recommended. Primary tumor resection in the setting of unresectable metastatic disease is more controversial, however generally recommended if morbidity is acceptable. For patients who are not surgical candidates, due to either patient performance status or burden of liver disease, several liver-directed therapies such as transarterial embolization, chemoembolization, and radioembolization are available to assist with locoregional control, extend progression-free survival (PFS), and improve symptoms of carcinoid syndrome. Multiple systemic therapy options exist for patients with metastatic PNET which are often prioritized for those patients with advanced or progressive disease. A systematic approach in a multi-disciplinary setting is likely to result in the best long-term outcomes for patients with pancreatic NELM. Ongoing research is needed to determine the optimal patient selection for hepatic surgery as well as the ideal treatment sequencing for those patients with NELM. |
---|---|
AbstractList | Pancreatic neuroendocrine tumors (PNET) are a heterogeneous group of neoplasms that vary in their clinical presentation, behavior and prognosis. The most common site of metastasis is the liver. Surgical resection of neuroendocrine liver metastases (NELM) is thought to afford the best long-term outcomes when feasible. Initial preoperative workup should include surveillance for carcinoid syndrome, screening for evidence of liver insufficiency, and performance of imaging specific to neuroendocrine tumors such as a somatostatin receptor positron emission tomography scan. Standard surgical principles apply to hepatic surgery for NELM, namely prioritizing low central venous pressure anesthesia, minimizing blood loss, knowledge of liver anatomy, generous use of intraoperative ultrasound, as well as safe parenchymal transection techniques and practices to avoid bile leakage. Knowledge of established prognostic factors may assist with patient selection, which is important for optimizing short- and long-term outcomes of hepatic resection. Adjunct therapies such as concomitant liver ablation are used frequently and are generally safe when used appropriately. For patients with synchronous resectable NELM, resection of the primary either in a staged or combined fashion is recommended. Primary tumor resection in the setting of unresectable metastatic disease is more controversial, however generally recommended if morbidity is acceptable. For patients who are not surgical candidates, due to either patient performance status or burden of liver disease, several liver-directed therapies such as transarterial embolization, chemoembolization, and radioembolization are available to assist with locoregional control, extend progression-free survival (PFS), and improve symptoms of carcinoid syndrome. Multiple systemic therapy options exist for patients with metastatic PNET which are often prioritized for those patients with advanced or progressive disease. A systematic approach in a multi-disciplinary setting is likely to result in the best long-term outcomes for patients with pancreatic NELM. Ongoing research is needed to determine the optimal patient selection for hepatic surgery as well as the ideal treatment sequencing for those patients with NELM. |
Author | Pawlik, Timothy M. Cloyd, Jordan M. Wiseman, Jason T. |
Author_xml | – sequence: 1 givenname: Jordan M. surname: Cloyd fullname: Cloyd, Jordan M. – sequence: 2 givenname: Jason T. surname: Wiseman fullname: Wiseman, Jason T. – sequence: 3 givenname: Timothy M. surname: Pawlik fullname: Pawlik, Timothy M. |
BookMark | eNpVkMtLxDAQxoOs-Fg9e-3RS9dJpm2ai7CIL1jwoIK3kGYna5c2WZNW8L-3PhAcBmZgPr5v-B2zmQ-eGDvjsBAcUF5sN2EhgKsF5wsQe-xICK7ySqqX2bSDrPOqVvyQnaa0hakKVUIpDtghiqosFdZHbPk4xk1rTZf1xpsN9eSHLLhsZ7yNZIbWZp7GGMivg42tp6xr3ylmPQ0mTU3phO070yU6_Z1z9nxz_XR1l68ebu-vlqvcooQht05ZdIqXdSkMKmNRgJMgGqBCciEa3riishUYadGgAweNWePaUYNYcMQ5u_zx3Y1NT2s7PRpNp3ex7U380MG0-v_Ft696E961xAJqKCeD81-DGN5GSoPu22Sp64ynMCYtCoElR5Bykl78SG0MKUVyfzEc9Dd7PbHXX-w15xoEfgJSKnmQ |
CitedBy_id | crossref_primary_10_1016_j_beem_2023_101798 crossref_primary_10_1038_s41572_021_00261_6 crossref_primary_10_1007_s40618_021_01705_2 crossref_primary_10_1097_MPA_0000000000002014 crossref_primary_10_3390_ijms23031109 crossref_primary_10_1016_j_amjsurg_2023_09_035 crossref_primary_10_1097_MPA_0000000000002320 crossref_primary_10_1016_j_lers_2023_06_001 crossref_primary_10_1097_RCT_0000000000001596 crossref_primary_10_1111_jne_13211 crossref_primary_10_3390_cancers14092312 crossref_primary_10_1097_JP9_0000000000000141 crossref_primary_10_1245_s10434_024_15129_8 crossref_primary_10_3390_jcm12247557 crossref_primary_10_1007_s00104_022_01656_1 crossref_primary_10_1245_s10434_020_09133_x crossref_primary_10_1007_s11912_022_01200_8 crossref_primary_10_1007_s12328_022_01689_3 crossref_primary_10_1007_s11605_022_05337_6 |
ContentType | Journal Article |
Copyright | 2020 Journal of Gastrointestinal Oncology. All rights reserved. 2020 Journal of Gastrointestinal Oncology. |
Copyright_xml | – notice: 2020 Journal of Gastrointestinal Oncology. All rights reserved. 2020 Journal of Gastrointestinal Oncology. |
DBID | AAYXX CITATION 7X8 5PM |
DOI | 10.21037/jgo.2019.11.02 |
DatabaseName | CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Anatomy & Physiology |
EISSN | 2219-679X |
EndPage | 600 |
ExternalDocumentID | 10_21037_jgo_2019_11_02 |
GroupedDBID | 04C AAWTL AAYXX ADBBV ALMA_UNASSIGNED_HOLDINGS BAWUL BMSDO CITATION DIK GX1 HYE M~E OK1 RNS RPM 7X8 5PM |
ID | FETCH-LOGICAL-c370t-cf9c3f915852a39ac320f702b0e47122b1bf46c60a7c3a3f0f0bad3dfeb334133 |
IEDL.DBID | RPM |
ISSN | 2078-6891 |
IngestDate | Fri Sep 01 02:29:40 EDT 2023 Fri Aug 16 02:11:36 EDT 2024 Fri Aug 23 02:53:04 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | true |
Issue | 3 |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c370t-cf9c3f915852a39ac320f702b0e47122b1bf46c60a7c3a3f0f0bad3dfeb334133 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 Contributions: (I) Conception and design: JM Cloyd, TM Pawlik; (II) Administrative support: JM Cloyd, TM Pawlik; (III) Provision of study materials or patients: All authors; (IV) Collection and assembly of data: JM Cloyd, JT Wiseman; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. |
OpenAccessLink | https://jgo.amegroups.com/article/viewFile/33556/pdf |
PMID | 32655938 |
PQID | 2423513077 |
PQPubID | 23479 |
PageCount | 11 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_7340805 proquest_miscellaneous_2423513077 crossref_primary_10_21037_jgo_2019_11_02 |
PublicationCentury | 2000 |
PublicationDate | 2020-6-00 20200601 |
PublicationDateYYYYMMDD | 2020-06-01 |
PublicationDate_xml | – month: 06 year: 2020 text: 2020-6-00 |
PublicationDecade | 2020 |
PublicationTitle | Journal of gastrointestinal oncology |
PublicationYear | 2020 |
Publisher | AME Publishing Company |
Publisher_xml | – name: AME Publishing Company |
SSID | ssj0000495052 |
Score | 2.3232315 |
SecondaryResourceType | review_article |
Snippet | Pancreatic neuroendocrine tumors (PNET) are a heterogeneous group of neoplasms that vary in their clinical presentation, behavior and prognosis. The most... |
SourceID | pubmedcentral proquest crossref |
SourceType | Open Access Repository Aggregation Database |
StartPage | 590 |
SubjectTerms | Review (Pancreatic Neuroendocrine Tumors) |
Title | Surgical management of pancreatic neuroendocrine liver metastases |
URI | https://search.proquest.com/docview/2423513077 https://pubmed.ncbi.nlm.nih.gov/PMC7340805 |
Volume | 11 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1NTwIxEJ0IB-PF-Bnxg9TEGC8L3Xah9kiIaEwwHiThtmm7rULchfBx8N877QLC1fNmN5vZaee97ps3AHdSiThRGa5v7myUMEUjjagf15V0Cc9iK4PFRv-t_TJIXoet4R601r0wQbRv9KhRfOeNYvQVtJXT3DTXOrHme78reIJAp9WsQEVwvkXRxyXk9cPZ_FA5LH9R-1HGpaUPC2Y-40_f8hfLhvfu9LNsEL8gqvb9KduF6Q9t7molt4pP7wgOV6iRdMq3O4Y9W5zAaadAxpz_kHsSdJzhgPwE9vur3-WnuGcuZ2FnI_lG5UImjuAOUIJFQ4KfpS2yifFtgOTbyzRIbhcKUePczs9g0Hv66L5Eq5kJkeGCLiLjpOFOxsgCmOJSGc6oE5RparEMMaZj7ZK2aVMlDFfcUUe1ynjmkFT7gsbPoVpMCnsBRAqaJQLpDDcykSZTWM6F0TpmzuDXlTV4WAcsnZbWGClSihDmFMOc-jAjw0gpq8HtOqAppq__J6EKO1nOUw_nWlhHhaiB2In05pneAHv3CuZFMMJe5cHlv--8ggPm-XM4VbmG6mK2tDcIMha6DpXnYVwPqfUL57nS1w |
link.rule.ids | 230,315,733,786,790,891,27957,27958,53827,53829 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3PT9swFH5iILFdxs9pHbAZCSEuSR07rfERIVBhFHEAxC2yHZuVkbRq08P21-_ZaaDlxs5WokTPz-_77M_fAziQSiSpyjG_ubNRyhSNNKJ-zCvpUp4nVgaLjf51t3eXXj50Hpag09yFCaJ9owdx-VzE5eBX0FaOCtNudGLtm_6p4CkCnU77A6xgvjIxR9KfatDr27P5tnJYAKPusUxqUx8W7HyeHv2lv0TG3r3Td7NBBIO42t9QmS9Nr3hzUS05V37O1-C--fBadfI7nlY6Nn_feDq--8_W4fMMkJKTengDlmy5CVsnJZLx4g85JEEiGvbeN2G1PzuJ38LleDoOiyYpXgQ0ZOgILi41DjUkWGXaMh8af8OQPHsFCClspRCQTuxkG-7Oz25Pe9GsHUNkuKBVZJw03MkECQZTXCrDGXWCMk0tVjjGdKJd2jVdqoThijvqqFY5zx3ydV8r-RdYLoel_QpECpqnApkSNzKVJleIFITROmHO4MSRLThqIpGNateNDNlKiF-G8ct8_JC8ZJS1YL-JVIaZ4Y87VGmH00nmkWIHS7QQLRALIXx5p_fWXhzBwASP7Vkgvv33kz_gY--2f5VdXVz_3IFPzNP0sHmzC8vVeGr3EMtU-nuYuf8A6R3z2Q |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1NTxsxEB0VKiEuLeVDpB_USBXishuvvYnrIwKiFAjiABLisrK9NiRkNxHZHODXd-xN0qRHzvuhXY3H8579_Abgl1QiSVWO-c2djVKmaKQR9WNeSZfyPLEyWGz0rtvdu_TivnW_1OoriPaN7sflsIjL_lPQVo4L05zrxJo3vVPBUwQ6reY4d801-Ig5y-QSUR_UwNe3aPOt5bAIRu3fMqmNfViw9Bk8-oN_iYy9g6fvaIMoBrG1P6WyXJ7-Yc5VxeRSCep8hof5x9fKk-d4WunYvP3n6_iuv9uCTzNgSk7qW77AB1tuw85JiaS8eCVHJEhFwxr8Nmz0ZjvyOzgtT1_C5EmKhZCGjBzBSabGo4YEy0xb5iPjTxqSoVeCkMJWCoHpxE524a5zfnvajWZtGSLDBa0i46ThTiZINJjiUhnOqBOUaWqx0jGmE-3StmlTJQxX3FFHtcp57pC3-5rJ92C9HJV2H4gUNE8FMiZuZCpNrhAxCKN1wpzBASQbcDyPRjau3TcyZC0hhhnGMPMxRBKTUdaAw3m0MswQv-2hSjuaTjKPGFtYqoVogFgJ4-Kd3mN79QoGJ3htz4Lx9d1P_oSNm7NOdvXn-vIbbDLP1sMazndYr16m9gdCmkofhMH7F5TB9lk |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Surgical+management+of+pancreatic+neuroendocrine+liver+metastases&rft.jtitle=Journal+of+gastrointestinal+oncology&rft.au=Cloyd%2C+Jordan+M.&rft.au=Wiseman%2C+Jason+T.&rft.au=Pawlik%2C+Timothy+M.&rft.date=2020-06-01&rft.issn=2078-6891&rft.eissn=2219-679X&rft.volume=11&rft.issue=3&rft.spage=590&rft.epage=600&rft_id=info:doi/10.21037%2Fjgo.2019.11.02&rft.externalDBID=n%2Fa&rft.externalDocID=10_21037_jgo_2019_11_02 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2078-6891&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2078-6891&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2078-6891&client=summon |